Oculis Holding AG (OCS)

12.10 +0.03 (+0.21%) 市場開市。 截至 03:05PM EDT。

Oculis Holding AG

Bahnhofstrasse 7
Zug 6300
Switzerland
41 41 711 9325
https://oculis.com

版塊: Healthcare
行業: Biotechnology
全職員工: 36

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Riad Sherif M.B.A., M.D.	CEO & Director	無	無	1968
Ms. Sylvia Cheung	Chief Financial Officer	無	無	1975
Dr. Ramin Tadayoni M.D., Ph.D.	Chief Scientific Officer	無	無	無
Ms. Virginia R. Dean	Chief Human Resources Officer	無	無	1967
Dr. Bastian Dehmel M.D.	Chief Development Officer	無	無	1971
Mr. Páll Ragnar Jóhannesson	Chief Business Officer	無	無	1982
Ms. Rebecca Weil	Chief Commercial Officer	無	無	無
Dr. Snehal Shah Pharm.D.	President of Research & Development	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

公司管治

截至 無 止，Oculis Holding AG 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。